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Abstract  
 
Autism spectrum disorders are a group of neurodevelopmental disorders with a complex 
and heterogeneous etiology. Studies have shown that genetic factors play an important 
role in the aetiology of these diseases. Recently, de novo mutations, frameshifts and 
deletions have been described in the SHANK3 gene, also known as ProSAP2 gene, 
which encodes a synaptic scaffolding protein. All the participants of this study had 
normal karyotypes and underwent screening for Fragile-X syndrome. Subsequently, 
they were analyzed by direct sequencing of different points of exons 8 and 22 of the 
SHANK3 gene. None of the study participants presented with changes in these regions. 
These findings may be due to the fact that mutations, deletions and duplications of the 
SHANK3 gene are rare.  
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Introduction  
Autism Spectrum Disorders (ASDs) are a clinically complex group of childhood 
disorders that have firm evidence of an underlying genetic etiology.1 The group of 
ASDs includes autism, as well as Pervasive Developmental Disorder not otherwise 
specified (PDD-NOS) and Asperger’s syndrome.2 The diagnosis of ASDs is based on 
impairments in reciprocal social interaction and communication, and restricted and 
stereotyped patterns of interests and activities with abnormal development apparent 
within the first 3 years of life.3 The prevalence of ASDs is estimated at 1 per 150 
children.4 Cases are isolated or associated and a recognized cause is identified in ~10% 
of individuals, most commonly fragile-X syndrome, tuberous sclerosis and 
cytogenetically detectable chromosome abnormalities.5,6,7 Standard karyotype analyses 
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show chromosomal rearrangements in 3%-6% of cases, the most common being 
deletions and duplications on chromosomes 2q, 7q, 15q and 22q.8,9  
The SHANK3 gene, mapped on chromosome 22q13.3, has been extensively studied in 
this population. This gene encodes the postsynaptic density protein (PSD) specialized at 
excitatory synapses, where it may function as a master scaffolder forming large sheets 
that may well represent the platform for the construction of the PSD complex, where it 
binds directly to neuroligins.10,11 The PSD is usually located at the tip of dendritic 
protrusions of about 1-2 µm in length, termed dendritic spines, and separated from the 
presynaptic transmitter-containing terminal by the synaptic cleft. Thus shank proteins 
are not considered to provide a direct scaffolding function for transmitter receptors, but 
rather work indirectly by connecting different types of scaffold/receptor complexes, 
leading to the concept of a “master” or “higher order” scaffold. This view is strongly 
supported by different protein interactions in which Shank proteins are involved.12 In 
addition to their function of assembling the PSD during synaptogenesis, the SHANK3 
protein may play a role in synaptic plasticity and in the regulation of dendritic spine 
morphology.13 
SHANK3 mutations, deletions and duplications are rare, occurring in only 1.1% of 
patients with ASD. However, the genotype-phenotype correlation suggests that 
individuals with severe language and social impairment might be good candidates for 
SHANK3 mutation screening.14 
Two recent studies reported possible correlations between mutations or small 
cytogenetic rearrangements affecting the SHANK3 gene and an ASD phenotype chiefly 
characterized by severe verbal and social deficits. The first study found a deletion of 
142 Kb in intron 8, one frameshift mutation (E409X) in exon 21, a deletion of 800 kb, 
and R12C and R300C mutations in exons 1 and 8, respectively. 8 The second work 
reported a missense mutation (Q321R) in exon 8, a 15-nt deletion in exon 21 and 
deletions of 277 Kb, 3.2 Mb and 4.36 Mb in 22q13. 2  
The lack of one functional copy of the gene would thus lead to severe neurological 
deficits because individual neurons cannot provide enough Shank proteins for synapse 
development and maintenance. In addition, it makes sense that the amount of Shank 
protein in dendrites is tightly controlled, most likely by local synthesis derived from 
dendritically transported mRNAs, and activity-dependent degradation through the 
ubiquitin proteasome system.12 
This current pilot study evaluated exons 8 and 22 of the SHANK3 gene by direct 
sequencing.  
 
Subjects and Methods  
 
This study was approved by the Research Ethics Committee (CEP) of the Medicine 
School in São José do Rio Preto and CONEP (process 25000.015469/2007-59). After 
obtaining written informed consent from parents, a total of 30 (22 male and 8 female) 
unrelated individuals with ASDs were studied. These individuals, of mixed ethnicity 
and representative of the Brazilian population, were aged from 5 to 30 years old (mean 
= 14.16 and standard deviation = 6.30 years). Fifteen (50%) were diagnosed as autistic, 
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11 (36.67%) with PDD-NOS and 4 (13.33%) with Asperger’s syndrome. The patients 
were from two specialized autism schools and all individuals were conclusively 
diagnosed by psychiatrists using different methods. Additionally, all were evaluated by 
an interdisciplinary team composed of a psychiatrist, neurologist, geneticist, 
psychologist, speech therapist and nurse before participating in this study. Besides the 
clinical evaluation, the diagnosis of ASD was made if the patient met the DSM-IV 
criteria. Patients were submitted to clinical and karyotypic examinations and molecular 
investigations of the FMR1 gene. Only those individuals with normal results for these 
tests were included in the study. We also excluded patients with evidence of any other 
psychiatric or neurological conditions and those with other genetic syndromes. Genomic 
DNA was isolated from the leukocytes of peripheral blood15 and the primer sequences 
were designed using the Primer3 program. 
For all patients, the entire exon 8 and parts of the coding region of exon 22 of the 
SHANK3 gene were screened. 
Exon 8 was targeted using the forward and reverse primers (5´-
CAGCTGTGATTCCCTCTTCC-3´ and 5´-GGGAAGAACCAAGGTTCAGA-3´) 
flanking the positions 8671 and 8870 of DNA producing an amplification of 200 bp. 
Exon 22 was targeted using two pairs of primers; the first flanked the positions 46748 
and 46934 of DNA, producing an amplification of 186 pb (forward primer 5´- 
GAAGTCACCCGAGGACAAGA-3´ and reverse primer 5´- 
CACAGCCGCTGACTGCAT-3´) and the second flanked the positions 47435 and 
47617 of DNA, producing an amplification of 183 pb (forward primer 5´- 
CAAGCCCAAGCTCAAGTCC-3´ and reverse primer 5´- 
GGGAAGAACCAAGGTTCAGA -3´). 
 Amplification was performed in a reaction volume of 25µL containing 1x PCR Buffer, 
50mM of MgCl2, 1.25mM dNTPs (GE Healthcare), 50ng genomic DNA, 10µM of each 
primer, and 5U Taq DNA polymerase (Invitrogen). The PCR reaction was carried out in 
a GeneAmp® PCR System 9700 (Applied Biosystems, CA) with 4 min of denaturation 
at 94ºC, followed by 35 cycles of 94ºC for 45s, 45s at an annealing temperature of 62ºC, 
and for exon 8, an extension for 1 min at 72ºC, with 5 min denaturation at 95ºC, 
followed by 30 cycles of 95ºC for 30s, 30s at the annealing temperature at 57ºC, and for 
each primers of exon 22, extension for 1 min at 72ºC. 
PCR products were purified with ethanol. 16 Sequencing reactions were carried out with 
the Applied Biosystems Dye-Terminator v3.1 Kit (Applied Biosystems, USA) and 
analyzed on a 3730 DNA analyzer (Applied Biosystems, CA). Analysis of sequences 
was performed using the DS Gene 2.0 program (Accelrys, USA) and a comparison with 
existing sequences was made using GenBank 
(www.ncbi.nlm.nih.gov/nuccore/24137474). 
To date 30 individuals have been investigated. Karyotyping was performed when 
possible on probands resulting in 27 individuals and 9 subjects for molecular genetic 
testing of the Fragile-X syndrome with one affected individual in each family. Direct 
sequencing of exon 8 and two exon 22 regions of the SHANK3 gene was performed for 
all subjects. 
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Results 
 
All subjects had wild sequences according to Genbank. Thus, all participants had 
normal sequences from 8700 to 8870, the position of exon 8 in the SHANK3 gene. 
Furthermore, they were normal considering the regions from 46748 to 46934 and from 
47435 to 47617 positions of DNA of exon 22 of the SHANK3 gene when analyzed by 
direct sequencing.  
 
Discussion 
 
SHANK3 is located on chromosome 22q13.3, spans approximately 57kb and contains 23 
exons. Seven of the exons are alternatively spliced, which may influence the spectrum 
of SHANK-interacting proteins. SHANK3 expression in the brain seems to be confined 
to the cortex, hippocampus and cerebellum.17 Owing to its emerging role in 
neuropsychiatric disorders, SHANK3 was first implicated in the field of neuro-
psychiatric disorders when a patient with 22q13.3 deletion syndrome was found to have 
a de novo reciprocal translocation that disrupted the gene. Subsequent studies have 
identified de novo deletions and mutations of SHANK3 in individuals with autism, thus 
corroborating with previous reports about the role of the gene within the autistic 
phenotype.18   
Exon 8 of the SHANK3 gene has 78 pb and exon 21 has 2254 pb. A de novo mutation 
has been described in exon 8, characterized by the exchange of A962G mRNA, which 
resulted in a heterozygous Q321R substitution.2 In this study the entire exon 8 was 
screened in all participants but no changes were identified.  
A frameshift mutation (E409X) and a 15-nt deletion have also been found in exon 21.2,8 
We initially chose to study this site (exon 21) as it had previously been reported as 
disrupted2,8, but the sequences of primers described by the authors correspond to exon 
22 of the human SHANK3 gene according to GenBank data. In personal correspondence 
with Christian R. Marshall, one of authors, it was noted that the sequence described was 
correct, but that it corresponded to exon 22 instead of 21. Thus, we chose to study parts 
of exon 22 and all the subjects were normal. 
A correlation between mutations or small cytogenetic rearrangements affecting different 
exons of SHANK3 and ASD is possible.2,14,19 Based on diagnostic tests, karyotyping and 
fragile-X testing must be requested for all patients with ASD. In the presence of 
dysmorphic features and evident neurological symptoms, it is reasonable to suspect the 
chromosomal rearrangements exist even if the karyotype appears normal. Depending 
upon availability and cost, BAC or CGH analysis is strongly advised in these cases. As 
these technologies will become progressively more available, it will be important not to 
restrict them to patients with dysmorphia, as microdeletions and microduplications are 
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also common among patients with idiopathic, non-dysmorphic ASD.14 However genetic 
screening is a powerful tool when dealing with monogenic Mendelian disorders that are 
characterized by direct genotype-phenotype correlations. In the case of complex 
disorders, such as ASD, widespread genetic testing would not only be expensive and 
time-consuming, but also generally inappropriate due to the etiological complexity.20  
Our findings were normal possibly due to the fact that mutations, deletions and 
duplications in SHANK3 are rare events, only occurring in approximately 1.1% of 
individuals with ASD 14,18,21 and in this pilot study we investigated a small number of 
Brazilian subjects. Sykes et al. (2009)21 not found SNP and copy number variants 
(CNVs) in SHANK3 but so rare mutations potencially could have been missed within 
the gene, cause sequense analysis was not conducted, but we did and not found too. 
There are numerous and variable changes in ASD, involving different chromosomal 
regions and many genes have been proposed as candidates including the one 
investigated here. Maybe genetic screening programs for the SHANK3 gene could be 
implemented but not for all patients with ASD, only for those patients with severe 
verbal and social deficits bearing in mind that some SHANK3 mutations have also been 
found to be transmitted to unaffected siblings of ASD probands.2  
The etiological complexity results in misinformation about what deserves to be initially 
included in the protocols of laboratory investigations of affected individuals. 
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